<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01697267</url>
  </required_header>
  <id_info>
    <org_study_id>RITAZAREM</org_study_id>
    <secondary_id>2012-001102-14</secondary_id>
    <nct_id>NCT01697267</nct_id>
  </id_info>
  <brief_title>Rituximab Vasculitis Maintenance Study</brief_title>
  <acronym>RITAZAREM</acronym>
  <official_title>An International, Open Label, Randomised Controlled Trial Comparing Rituximab With Azathioprine as Maintenance Therapy in Relapsing ANCA-associated Vasculitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cambridge University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Arthritis Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cambridge University Hospitals NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rituximab is now established as an effective drug for anti-neutrophil cytoplasmic antibody
      (ANCA) vasculitis following major European and US trials reported in 2010. After a time, its
      effect wears off and the disease can return. This occurs in at least half of patients within
      2 years of receiving Rituximab. A preliminary study in Cambridge has suggested that repeating
      rituximab every six months stops the disease returning and is safe.

      The RITAZAREM trial will find out whether repeating rituximab stops vasculitis returning and
      whether it works better than the older treatments, azathioprine or methotrexate. It will also
      tell us how long patients remain well after the repeated rituximab treatments are stopped,
      and if repeated rituximab is safe. We should also learn useful information about the effects
      of rituximab on quality of life and economic measures. The trial results will help decide the
      best treatment for future patients who have their vasculitis initially treated with
      rituximab.

      RITAZAREM aims to recruit patients with established ANCA vasculitis whose disease has come
      back 'relapsing vasculitis'. All patients will be treated with rituximab and steroids and we
      anticipate that most will respond well. If their disease is under reasonable control after
      four months, further treatment with either rituximab (a single dose ever four months for two
      years) or azathioprine tablets will be chosen randomly. The patients in the rituximab and
      azathioprine groups will then be compared. Patients will be in the trial for four years.

      The study has been designed by members of the European Vasculitis Study group (EUVAS) and the
      Vasculitis Clinical Research Consortium (VCRC). It will include 190 participants from 30
      hospitals in Europe, the USA, Australia and Mexico.

      RITAZAREM is being funded by Arthritis Research UK, the U.S. National Institutes of Health
      and by Roche/Genentech.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be recruited at the time of relapse. All will receive rituximab 375 mg/m2/week
      x 4 and glucocorticoids.

      Those patients that achieve disease control (BVAS/WG ≤ 1 and daily prednisone dose ≤ 10 mg)
      by month 4 will be randomised to the rituximab or control remission maintenance groups.

      Treatment is protocolised for the entire duration of the study, until the common close date,
      when the final patient recruited has completed 36 months within the study or until the
      patient has completed 48 months on study whichever the sooner. Patients in the rituximab arm
      will receive treatment until month 20, and those in the azathioprine arm until month 27.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to relapse</measure>
    <time_frame>Any patients who have not relapsed at up to a maximum of 4 years will be censored.</time_frame>
    <description>The primary endpoint is the time to disease relapse (either minor or major relapse) from randomisation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Remission at 24 and 48 months</measure>
    <time_frame>24 and 48 months</time_frame>
    <description>Proportion of patients who maintain remission at 24 and 48 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined damage assessment score</measure>
    <time_frame>Assessed at months 0, 4, 12, 24, 36</time_frame>
    <description>Cumulative accrual of damage as measured by the combined damage assessment score (CDA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>Assessed at months 0, 4, 12, 24, 36</time_frame>
    <description>Health-related quality of life as measured using SF-36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative GC exposure</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Cumulative glucocorticoid (GC) exposure during the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe adverse event rate</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Severe adverse event (SAE) rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection rates</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Infection (treated with intravenous or oral antibiotics) rates</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</condition>
  <condition>Microscopic Polyangiitis</condition>
  <condition>Wegener Granulomatosis</condition>
  <arm_group>
    <arm_group_label>Rituximab Maintenance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituximab maintenance: 1g at 4, 8, 12, 16 &amp; 20 months with standardised steroid taper</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azathioprine Maintenance</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Azathioprine Maintenance: 2mg/kg/day with standardised steroid taper, from month 4 (randomisation) (200 mg maximum daily dose). Azathioprine withdrawn at month 27.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab IV infusion 1000 mg x 1 dose at months 4, 8, 12, 16 and 20 and glucocorticoids. Four - six hour infusion. Treatment with rituximab will cease at month 20.</description>
    <arm_group_label>Rituximab Maintenance</arm_group_label>
    <other_name>Rituxan</other_name>
    <other_name>MabThera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azathioprine</intervention_name>
    <description>Oral dosage form. Target dose is 2mg/kg; maximum daily dose is 200mg. This should be continued until month 24. The dose should then by reduced by 50% and azathioprine completely withdrawn at month 27.
The dose should be rounded down to the nearest 25mg. The dose may vary on alternate days e.g. 100mg one day, 150mg the next for patients on an overall dose of 125mg daily.
If patients are aged over 60 years, reduce the dose by 25%. If patients are aged over 75 years, reduce the dose by 50%.</description>
    <arm_group_label>Azathioprine Maintenance</arm_group_label>
    <other_name>Imuran</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A diagnosis of AAV [granulomatosis with polyangiitis or microscopic polyangiitis],
             according to the definitions of the Chapel Hill Consensus Conference

          2. Current or historical PR3/MPO ANCA positivity by ELISA

          3. Disease relapse defined by one major or three minor disease activity items on the
             Birmingham Vasculitis Activity Score for Wegeners (BVAS/WG), in patients that have
             previously achieved remission following at least 3 months of induction therapy, with a
             combination of glucocorticoids and an immunosuppressive agent (cyclophosphamide or
             methotrexate or rituximab or mycophenolate mofetil)

          4. Written informed consent

        Exclusion Criteria:

          1. Age &lt; 15 years (age &lt; 18 years at centres that do not treat paediatric patients)

          2. Exclusions related to medication:

             Previous therapy with:

               1. Any biological B cell depleting agent (such as rituximab or belimumab) within the
                  past 6 months

               2. Alemtuzumab or anti-thymocyte globulin (ATG) within the last 12 months

               3. IVIg, infliximab, etanercept, adalimumab, abatacept or plasma exchange in past 3
                  months

               4. Any investigational agent within 28 days of screening, or 5 half lives of the
                  investigational drug (whichever is longer)

          3. Exclusions related to general health:

               1. Significant or uncontrolled medical disease not related to AAV, which in the
                  investigators opinion would preclude patient participation

               2. Presence of another multisystem autoimmune disease, including Churg Strauss
                  syndrome, systemic lupus erythematosus, anti-GBM disease, or cryoglobulinaemic
                  vasculitis,

               3. Any concomitant condition anticipated to likely require greater than 4 weeks per
                  year of oral or systemic glucocorticoid use and which would preclude compliance
                  with the glucocorticoid protocol (e.g. poorly-controlled asthma, COPD, psoriasis,
                  or inflammatory bowel disease).

               4. History of severe allergic or anaphylactic reactions to humanised or murine
                  chimeric monoclonal antibodies

               5. Known infection with HIV (HIV testing will not be a requirement for trial entry);
                  a past or current history of hepatitis B virus or hepatitis C virus infection.

               6. Ongoing or recent (last 12 months) evidence of active tuberculosis or known
                  active infection (screening for tuberculosis is part of &quot;standard of care‟ in
                  patients with established AAV) or evidence of untreated latent tuberculosis.
                  Screening for tuberculosis is as per local practice.

               7. History of malignancy within the past five years or any evidence of persistent
                  malignancy, except fully excised basal cell or squamous cell carcinomas of the
                  skin, or cervical carcinoma in situ which has been treated or excised in a
                  curative procedure.

               8. Pregnancy or inadequate contraception in pre-menopausal women

               9. Breast feeding or lactating

          4. Exclusion criteria related to laboratory parameters:

               1. Bone marrow suppression as evidenced by a total white count &lt; 4 x109/l,
                  haemoglobin &lt; 7 gm/dl or platelet count &lt; 100,000/μl

               2. Aspartate aminotransferase or alanine aminotransferase or amylase &gt; 2.5 times the
                  upper limit of normal, unless attributed to vasculitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Jayne</last_name>
    <role>Study Chair</role>
    <affiliation>Cambridge University Hospitals NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Merkel</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canberra Hospital</name>
      <address>
        <city>Garran</city>
        <state>Australian Capital Territory</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane &amp; Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 3L9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Faculty Hospital</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cork University Hospital</name>
      <address>
        <city>Wilton</city>
        <state>Cork</state>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Parma</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama University</name>
      <address>
        <city>Kita Ward</city>
        <state>Okayama</state>
        <zip>700-0082</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiba University</name>
      <address>
        <city>Chiba-shi</city>
        <zip>263-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kitano Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miyazaki</name>
      <address>
        <city>Miyazaki</city>
        <zip>889-2192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teikyo University</name>
      <address>
        <city>Tokyo</city>
        <zip>173-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Metropolitan Geriatric</name>
      <address>
        <city>Tokyo</city>
        <zip>173-0015</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyorin University school of medicine</name>
      <address>
        <city>Tokyo</city>
        <zip>192-0005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Grafton</city>
        <state>Auckland</state>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Hospital</name>
      <address>
        <city>Westlake</city>
        <state>Auckland</state>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester General Hospital</name>
      <address>
        <city>Leicester</city>
        <state>Leicestershire</state>
        <zip>LE5 4PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2WB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brighton and Sussex University Hospitals</name>
      <address>
        <city>Brighton</city>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russells Hall Hospital</name>
      <address>
        <city>Dudley, West Midlands</city>
        <zip>DY1 2HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ipswich Hospital</name>
      <address>
        <city>Ipswich</city>
        <zip>IP4 5PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chapel Allerton Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS7 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Cook University Hospital</name>
      <address>
        <city>Middlesbrough</city>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Centre Campus, Nottingham University Hosp</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oxford</name>
      <address>
        <city>Oxford</city>
        <zip>OX1 2JD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>New Zealand</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.rarediseasesnetwork.org/VCRC/RITAZAREM</url>
    <description>RITAZAREM trial information with links to CRFs, protocol synposis, and other trial-related information</description>
  </link>
  <reference>
    <citation>Watts RA, Suppiah R, Merkel PA, Luqmani R. Systemic vasculitis--is it time to reclassify? Rheumatology (Oxford). 2011 Apr;50(4):643-5. doi: 10.1093/rheumatology/keq229. Epub 2010 Jul 20.</citation>
    <PMID>20647295</PMID>
  </reference>
  <reference>
    <citation>Falk RJ, Jennette JC. ANCA disease: where is this field heading? J Am Soc Nephrol. 2010 May;21(5):745-52. doi: 10.1681/ASN.2009121238. Epub 2010 Apr 15. Review.</citation>
    <PMID>20395376</PMID>
  </reference>
  <reference>
    <citation>Watts RA, Scott DG. Epidemiology of the vasculitides. Curr Opin Rheumatol. 2003 Jan;15(1):11-6. Review.</citation>
    <PMID>12496504</PMID>
  </reference>
  <reference>
    <citation>Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, Plaisance M, Pusey CD, Jayne DR; Pan-Thames Renal Research Group. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis. 2003 Apr;41(4):776-84. Review.</citation>
    <PMID>12666064</PMID>
  </reference>
  <reference>
    <citation>Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniené J, Ekstrand A, Gaskin G, Gregorini G, de Groot K, Gross W, Hagen EC, Mirapeix E, Pettersson E, Siegert C, Sinico A, Tesar V, Westman K, Pusey C; European Vasculitis Study Group. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003 Jul 3;349(1):36-44.</citation>
    <PMID>12840090</PMID>
  </reference>
  <reference>
    <citation>de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, Luqmani R, Pusey CD, Rasmussen N, Sinico RA, Tesar V, Vanhille P, Westman K, Savage CO; EUVAS (European Vasculitis Study Group). Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009 May 19;150(10):670-80.</citation>
    <PMID>19451574</PMID>
  </reference>
  <reference>
    <citation>De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, Gross WL, Luqmani R, Jayne DR. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005 Aug;52(8):2461-9.</citation>
    <PMID>16052573</PMID>
  </reference>
  <reference>
    <citation>Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med. 2005 Jan 27;352(4):351-61.</citation>
    <PMID>15673801</PMID>
  </reference>
  <reference>
    <citation>Seo P, Min YI, Holbrook JT, Hoffman GS, Merkel PA, Spiera R, Davis JC, Ytterberg SR, St Clair EW, McCune WJ, Specks U, Allen NB, Luqmani RA, Stone JH; WGET Research Group. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis Rheum. 2005 Jul;52(7):2168-78.</citation>
    <PMID>15986348</PMID>
  </reference>
  <reference>
    <citation>Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994 Jan 15;83(2):435-45.</citation>
    <PMID>7506951</PMID>
  </reference>
  <reference>
    <citation>Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR; European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010 Jul 15;363(3):211-20. doi: 10.1056/NEJMoa0909169.</citation>
    <PMID>20647198</PMID>
  </reference>
  <reference>
    <citation>Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010 Jul 15;363(3):221-32. doi: 10.1056/NEJMoa0909905.</citation>
    <PMID>20647199</PMID>
  </reference>
  <reference>
    <citation>Jones RB, Ferraro AJ, Chaudhry AN, Brogan P, Salama AD, Smith KG, Savage CO, Jayne DR. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2009 Jul;60(7):2156-68. doi: 10.1002/art.24637.</citation>
    <PMID>19565480</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2012</study_first_submitted>
  <study_first_submitted_qc>October 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2012</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cambridge University Hospitals NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>David Jayne</investigator_full_name>
    <investigator_title>Director, Vasculitis and Lupus Clinic</investigator_title>
  </responsible_party>
  <keyword>vasculitis</keyword>
  <keyword>ANCA vasculitis</keyword>
  <keyword>microscopic polyangiitis</keyword>
  <keyword>granulomatosis</keyword>
  <keyword>Wegener's</keyword>
  <keyword>AAV</keyword>
  <keyword>vasculitides</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasculitis</mesh_term>
    <mesh_term>Systemic Vasculitis</mesh_term>
    <mesh_term>Granulomatosis with Polyangiitis</mesh_term>
    <mesh_term>Microscopic Polyangiitis</mesh_term>
    <mesh_term>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

